Mice were subcutaneously inoculated with 1 × 106 B16F10 tumor cells and randomized into the following systemic treatment groups: vehicle, anti-CTLA-4, TPPU, or a combination of anti-CTLA-4 and TPPU. Here, CTLA4 is linked to neoplasm.